BRNS

Barinthus is a pre-revenue, clinical-stage immunotherapy company whose financials describe a cash-burning research shell, not an investable business. FY2025 revenue was $0.00 (collapsing from $15.0M in FY2024 as the milestone/partnership income disappeared), while the net loss widened to -$66.4M and operating income was -$70.6M. The accumulated deficit is -$304M, ROE is -89.5%, and management states plainly it has 'incurred net losses in each annual and interim reporting period since 2023' and does 'not currently expect positive cash flows from operations in the foreseeable future.' There is no earnings power to value here — only a lead asset (VTP-1000, celiac, Phase 1) and a partner-seeking VTP-300 (hepatitis B, Phase 2).

The balance sheet buys time but not safety. Cash is $70.5M against ~$48M annual operating cash burn — roughly 1.5 years of runway — and total assets fell -38.8% YoY as the company spent down. Notably, the equity value (~40.8M shares × $0.62 ≈ $25M market cap) sits well below both stockholders' equity ($74.2M) and net cash ($70.5M): the market is pricing in continued burn, dilution, and uncertainty around the deal rather than a bargain. Debt is negligible (liabilities/equity 0.32x), so the risk is not leverage — it's runway erosion and the terms of what comes next.